Printer Friendly

The US FDA approves first generic EpiPen for the emergency treatment of allergic reactions.

Global Banking News-August 17, 2018-The US FDA approves first generic EpiPen for the emergency treatment of allergic reactions

(C)2018 ENPublishing - http://www.enpublishing.co.uk

Public health company The US Food and Drug Administration Thursday authorised the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds.

The US FDA's approval to market the generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths was awarded to Teva Pharmaceuticals USA.

Life-threatening allergies can include reactions to insect bites or stings, foods, medications, latex or other causes. Anaphylaxis is a medical emergency that affects the whole body and, in some cases, leads to death. People who have had an anaphylaxis episode must carry an emergency dose of epinephrine at all times.

According to the company, the EpiPen is intended to automatically inject a dose of epinephrine into a person's thigh to stop an allergic reaction. The US FDA has approved several epinephrine auto-injector products under new drug applications to treat anaphylaxis, including EpiPen, Adrenaclick and Auvi-Q.

Epinephrine auto-injector products are known as "combination products" because they consist of a drug (epinephrine) and a device (the auto-injector). When given intramuscularly or subcutaneously, it has a rapid onset and short duration of action,concluded the US FDA.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:Aug 17, 2018
Words:239
Previous Article:Sirnaomics Oncology wins US FDA's approval to initiate study of STP705 in cholangiocarcinoma patients.
Next Article:Ziylo acquired by Novo Nordisk for over USD800m.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters